(Q34854084)

4 August 2017

title

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer (English)

1 reference

4 August 2017

12

D Berney

1 reference

4 August 2017

T Powles

1

1 reference

4 August 2017

I Kayani

2

1 reference

4 August 2017

C Blank

3

1 reference

4 August 2017

S Chowdhury

4

1 reference

4 August 2017

S Horenblas

5

1 reference

4 August 2017

J Peters

6

1 reference

4 August 2017

J Shamash

7

1 reference

4 August 2017

N Sarwar

8

1 reference

4 August 2017

K Boletti

9

1 reference

4 August 2017

A Sadev

10

1 reference

4 August 2017

T O'Brien

11

1 reference

4 August 2017

L Beltran

13

1 reference

4 August 2017

J Haanen

14

1 reference

4 August 2017

A Bex

15

1 reference

4 August 2017

publication date

17 January 2011

1 reference

4 August 2017

1 reference

4 August 2017

volume

22

1 reference

4 August 2017

issue

5

1 reference

4 August 2017

page(s)

1041-1047

1 reference

Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy.

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082157

Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082157

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082157

UK guidelines for the systemic treatment of renal cell carcinoma.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082157

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082157

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082157

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082157

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082157

Sorafenib in advanced clear-cell renal-cell carcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082157

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082157

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082157

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082157

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082157

Sunitinib for treatment of advanced renal cell cancer: primary tumor response

8 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ564

Surgical resection of renal cell carcinoma after targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ564

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ564

Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ564

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21242586

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/ANNONC/MDQ564

1 reference

4 August 2017

1 reference

4 August 2017

1 reference